Upstream Bio develops verekitug, an experimental antibody drug for severe asthma, nasal polyps and COPD. It last closed at $2.10 on Nov 17, down 2.33% on the day. In the past 30 days there were 1 dark pool print totaling $282K, the largest $282K.
Only 1 firm rated UPB in the past 90 days, not enough for a consensus
Average 12-month target
$18.00
▲ 757.1% upside
Based on 1 analyst who set a price target on UPB in the past 90 days. The average target is $18.00, with a high of $18.00 and a low of $18.00, compared with the last close of $2.10.
Low $18.00Avg $18.00High $18.00
Blue marker: last close $2.10
Highest target$18.00
Average target$18.00
Lowest target$18.00
Latest rating changes
HC Wainwright & Co.Target lowered
Nov 11Buy$36 → $18
HC Wainwright & Co.Reiterated
Sep 2Buy$36
JP MorganTarget raised
Aug 14Hold$8 → $9
Truist SecuritiesMaintained
Aug 12Buy$25
JP MorganDowngrade
Jun 12Hold$8
Date
Firm
Action
Rating
Price target
Nov 11
HC Wainwright & Co.
Target lowered
Buy
$36 → $18
Sep 2
HC Wainwright & Co.
Reiterated
Buy
$36
Aug 14
JP Morgan
Target raised
Hold
$8 → $9
Aug 12
Truist Securities
Maintained
Buy
$25
Jun 12
JP Morgan
Downgrade
Hold
$8
Loading…
Technical Analysis
UPB · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 44% below its 20 day and 94% below its 50 day average. It is 262% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the 52 week low at $2.00, and the nearest resistance the Pivot R1 at $2.20.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 17.4%/day
Key levels
$33.6852 week high+1503.8%
$7.60200 day average+261.9%
$5.50100 day average+161.9%
$4.0850 day average+94.3%
$3.84Swing high (Nov 4)+82.9%
$3.0320 day average+44.3%
$2.20Pivot R1+4.8%
$2.10Pivot+0.0%
$2.10Last close
$2.0052 week low−4.8%
$2.00Pivot S1−4.8%
Indicators
RSI (14)
27.63
Oversold below 30
Oversold
MACD
-0.41
Below its signal line
Bearish
Stochastic
5.2
Near the bottom of its range
Oversold
ADX (14)
36.6
Trending down
Williams %R
-94.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-199.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−38.0%
Change over 10 sessions
Bearish
ATR (14)
$0.36
Typical daily range, 17.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchOversold
VolatilityHigh, 51.8%/day
Key levels
$33.6852 week high+1503.8%
$7.60200 day average+261.9%
$5.50100 day average+161.9%
$4.0850 day average+94.3%
$3.84Swing high (Nov 4)+82.9%
$3.0320 day average+44.3%
$2.20Pivot R1+4.8%
$2.10Pivot+0.0%
$2.10Last close
$2.0052 week low−4.8%
$2.00Pivot S1−4.8%
Indicators
RSI (14)
24.61
Oversold below 30
Oversold
MACD
-2.01
Below its signal line
Bearish
Stochastic
4.9
Near the bottom of its range
Oversold
ADX (14)
35.6
Trending down
Williams %R
-98.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-137.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−63.4%
Change over 10 sessions
Bearish
ATR (14)
$1.09
Typical daily range, 51.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for UPB
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how UPB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90D
No whale options trades in UPB in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether UPB is in one of them and how their past UPB trades turned out.
Upstream Bio is a biotechnology company based in Waltham, Massachusetts, that develops treatments for inflammatory diseases. Its main candidate, verekitug, is a monoclonal antibody that blocks the receptor for a protein called TSLP, which plays a role in immune responses. The company is testing verekitug in clinical trials for severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease. The drug is not yet approved, and its intended patients are people with these lung and airway conditions.